Patient Gateway

RSS Feed

Imagene AI and Mindpeak Collaborate to Bring AI-Powered NSCLC Biomarker Profiling into Digital Pathology Workflows

Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report

Cancer therapy-related cardiovascular toxicity observed during third-generation EGFR-TKI-based treatment in EGFR-mutant NSCLC: a retrospective cohort study

DECIDE-MET Trial: Targeted Therapy or Immunotherapy First in METex14 NSCLC?

Navigating Zidesamtinib Safety, Sequencing in ROS1+ NSCLC

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI

Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC

Beyond immune surveillance: IFN-γ and PD-L1 as shapers of tumor plasticity in Non-Small Cell Lung Cancer (NSCLC)

BCL2A1 marks an early, less-exhausted CD8+ tumor-infiltrating lymphocyte state associated with PD-1 blockade response in NSCLC